Effect of Human Chorionic Gonadotropin Injection Before Frozen Embryo Transfer on Pregnancy Outcomes in Endometriosis-Associated Infertility

Yanbo Du 1, Lei Yan 1,2,3, Mei Sun 1,4, Yan Sheng 1,4, Xiufang Li 1, Zhenhua Feng 1 and Rong Tang 1,4*

1 Reproductive Hospital Affiliated to Shandong University, Jinan, China, 2 School of Medicine, Shandong University, Jinan, China, 3 National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Key Laboratory of Reproductive Endocrinology, Shandong University, Ministry of Education, Jinan, China, 4 Shandong Provincial Hospital, Jinan, China

Purpose: The aim of this study was to investigate the effect of human chorionic gonadotropin (hCG) in hormone replacement (HT) regime for frozen thawed embryo transfer in women with endometriosis (EM).

Methods: We performed a retrospective, database-search, cohort study and included data on EM patients who underwent frozen embryo transfer (FET) between January 1, 2009 and August 31, 2018. According to the protocols for FET cycle, the patients were divided into two groups: control group (n = 296) and hCG group (n = 355). Clinical pregnancy rate, live birth rate, early abortion rate, late abortion rate, and ectopic pregnancy rate were compared between the two groups.

Results: There was a significant increase in clinical pregnancy rate in the hCG group (57.7 vs. 49%, p = 0.027) compared with the control group. The live birth rate in the hCG group (45.6 vs. 38.5%, p = 0.080) was also elevated, but this difference was not statistically significant.

Conclusion: hCG administration in HT regime for FET increases the pregnancy rate in women with EM.

Keywords: endometriosis, frozen embryo transfer, human chorionic gonadotropin, hormone replacement, assisted reproductive technology

INTRODUCTION

Endometriosis (EM) is a chronic gynecological disease characterized by lesions of endometrial-like tissue outside of the uterine cavity (1, 2). Almost 50% of women with EM experience infertility (3). EM affects the outcomes of assisted reproductive technology (ART). There are different factors involved in poor outcomes, including poor quality of oocyte and/or embryo, impaired receptivity of the endometrium, and implantation failure (4, 5). Clinically, there is little doubt that the endometrium of women with EM is less receptive to embryo implantation, and strong evidence suggests that endometrial changes are associated with decreased cycle fecundity (6).
Endometrial biomarkers are differentially expressed in the endometrium of women with EM compared with normal women (7, 8). Seeking an effective approach to improve endometrial receptivity in EM is a complex clinical issue.

Frozen embryo transfer (FET) is recommended for EM in ART. Mohamed et al. suggested that the preparation of the endometrium for FET with gonadotropin-releasing-hormone (GnRH) agonists could improve the live birth rate in EM compared with FET (9). Recently, Xu et al. found that pregnancy rate, clinical pregnancy rate, and birth weight were improved in women with EM who underwent intrauterine injection of human chorionic gonadotropin (hCG) before FET (10). However, these methods are either time-consuming or inconvenient. Therefore, we retrospectively analyzed the data on FET in patients with EM to determine a more effective strategy for FET. The aim of our study was to investigate the effect of hCG injection in hormone replacement (HT) regime on FET outcomes among patients with EM.

MATERIALS AND METHODS

Subjects
This retrospective, database-search, cohort study was conducted at the Reproductive Hospital Affiliated Shandong University, Shandong, China. This study was reviewed and approved by the research ethics committee of our institution. All included patients provided written informed consent for use of their data.

All patients who were diagnosed with laparoscopically confirmed EM and underwent FET in our hospital during a 9-year period (January 1, 2009 to August 31, 2018) were included in the study. However, the stage of EM was not clear, as the operation records were not provided. Patients older than 42 years at the onset of the cycle; with basal follicle stimulating hormone (FSH) level > 12 U/L; and with uterine malformation, chromosomal abnormalities, hydrosalpinx, recurrent spontaneous abortion, and submucosal fibroid or intrauterine adhesions were all excluded from the study. Finally, data on 651 women diagnosed with EM-associated infertility were collected. According to whether hCG injection was included in the protocols, the patients were divided into two groups—control group (n = 296) and hCG group (n = 355).

Endometrial Preparation
Patients in the control group received HT regime for FET. Oral estradiol valerate (Progynova, Delpharm Lille) at a dose of 4–8 mg/day was initiated on day 2 or 3 of the menstrual cycle and commonly lasted for 10–14 days to promote endometrial proliferation. The dosage and duration of estrogen were increased until the endometrial thickness reached an appropriate state for embryo transfer (commonly, at least 8 mm), at which time vaginal progesterin (200 mg/day Utrogestan, Besins Healthcare) and oral dydrogesterone (20 mg b.i.d Duphaston, Abbott) were added. Patients who received FET earlier than 2011 were treated with intramuscular injection of progesterone (Progesterone Injection, Zhejiang Xianju Pharmaceutical Co., Ltd) instead.

Embryo Transfer
According to the embryo morphology assessment by the Istanbul consensus workshop, blastocysts on day 5 with inner cell mass in the hatching stage and trophoderm layer (grade 1–2) were considered good embryos. While, as cleavage stage embryos, high-quality embryos were scored by morphologic criteria (11). Only good embryos were frozen and prepared for transfer. One or two cleavage-stage embryos or blastocysts frozen early were thawed and transferred 3 or 5 days, respectively, after progesterone initiation. Women in the hCG group received 8,000 IU hCG (HCG; Livzon) by intramuscular injection before progestin administration; the HT regime was the same as the control group. If conception was confirmed, estrogen was continued until 7 weeks of gestation, and progestin supplementation was continued until 10 weeks of gestation.

Outcomes
The primary outcome was clinical pregnancy, which was defined as the detection of an intrauterine gestational sac by transvaginal ultrasonography after 3 weeks of FET. The secondary outcome was live birth, which was defined as the delivery of a viable neonate that was at least of 28 gestational weeks. The early abortion rate was defined as the percentage of miscarriage occurring earlier than 12 weeks, whereas the late abortion rate was the proportion of miscarriage occurring between 12 and 28 weeks. Preterm birth rate was defined as the percentage of birth before 34 weeks in women with live birth. The live birth rate was the proportion of women who birthed at least one living child.

Statistical Analysis
Continuous variables were represented as means and standard deviations; differences in variables were compared by means of Student's t-test. Categorical variables were described as frequencies and percentages, with the between-group difference tested by means of the chi-square test and Fisher's exact test when the number of events was <5. A two-sided p-value < 0.05 was considered to indicate statistical significance.

RESULTS

Patients
The baseline characteristics were similar in the control and hCG groups (Table 1). There were no differences in terms of age, body mass index (BMI), basal endocrine hormone levels, number of oocytes retrieved in the fresh cycle, fertilization rate of oocytes, number of available embryos, and the percentage of patients with coexisting polycystic ovarian syndrome (PCOS) and adenomyosis between the two groups. However, the level of anti-Müllerian hormone (AMH) was lower in the hCG group than in the control group.

Outcomes of FET
The concentration of estrogen and luteinizing hormone (LH), the number and stage of transferred embryos, and the proportion of patients with recurrent endometrioma did not differ significantly between the two groups, but the endometrium was thicker in the hCG group than in the control group. FET outcomes were
improved in the hCG group. The pregnancy rate of the hCG group was significantly higher than that of the control group (57.7 vs. 49%, \( p = 0.027 \)) (Table 2). The live birth rate of the hCG group (45.6 vs. 38.5%, \( p = 0.080 \)) was also higher than that of the control group, but this difference was not statistically significant (Table 2). In addition, there was no significant difference in early abortion rate, late abortion rate, preterm birth rate, and ectopic pregnancy rate between the two groups (Table 2). In a multivariate logistic regression model, we analyzed various clinical factors of the patients, and we found that hCG treatment, the age of patients, and recurrent endometrioma with a diameter >3 cm were associated with the pregnancy rate of FET in EM patients (Table 3).

**DISCUSSION**

In our retrospective analysis, we found that hCG injection could significantly improve pregnancy rate in EM patients who underwent FET. Further, live birth rate was also elevated in the hCG group; however, the difference was not statistically significant.

LH/hCG receptors are detected in the glandular epithelium cells of the human endometrium (12), and hCG has been shown to promote human endometrium stromal cell decidualization when used in combination with progesterone (13). Transcription of hCG was found in two-cell-stage embryos (14), and the specific interaction of blastocyst-derived hCG and the endometrial LH/hCG receptors is a fundamental component in the materno-fetal interface dialogue (15). It has recently been reported that intratubine hCG could improve FET outcomes for EM patients (10). However, intramuscular injection of hCG, in HT regime in EM patients who underwent FET, has never been reported. We found that hCG intramuscular injection before FET in EM could also improve pregnancy rate, but have no effect on live birth rate. However, the administration of hCG was not beneficial for FET in human replacement cycles for non-EM patients. The main reason for this was assumed to be the distinctive characteristics of EM.

**TABLE 1 | Basal characteristics of participants.**

| Variable                  | Control group | hCG group | \( p \)-value |
|---------------------------|---------------|-----------|---------------|
| \( N \)                   | 296           | 355       |               |
| Age (years)               | 31.51 ± 4.33  | 31.39 ± 4.14 | 0.663        |
| BMI (kg/m\(^2\))          | 22.41 ± 3.96  | 22.92 ± 3.33 | 0.627        |
| AMH (ng/mL)               | 5.53 ± 5.38   | 5.14 ± 4.12  | 0.003        |
| Concurrent PCOS           | 50 (16.9%)    | 49 (13.8%) | 0.276        |
| Concurrent adenomyosis    | 4 (1.4%)      | 7 (2%)     | 0.762        |
| Basal FSH (U/L)           | 6.75 ± 2.97   | 6.50 ± 1.85  | 0.096        |
| Basal LH (U/L)            | 5.89 ± 3.47   | 5.73 ± 3.29  | 0.818        |
| Basal E2 (pg/mL)          | 42.93 ± 32.40 | 49.33 ± 111.5 | 0.103      |
| No. of oocyte retrieved   | 14.44 ± 7.96  | 13.87 ± 7.31 | 0.168        |
| Fertilization rate of oocytes | 69.4%     | 65.6%      | 0.639        |
| No. of available embryos  | 5.27 ± 3.33   | 4.75 ± 2.66  | 0.066        |

*There were no significant differences between the hCG group and the control group \( p > 0.05 \) in any of the baseline characteristics except AMH.*

**TABLE 2 | Outcomes of frozen embryo transfer.**

| Outcome                              | Control group | hCG group | \( p \)-value |
|--------------------------------------|---------------|-----------|---------------|
| Endometrium thickness                | 0.90 ± 0.30   | 0.92 ± 0.13 | 0.000        |
| Recurrent endometrioma               |               |           |               |
| Cyst diameter (<3 cm)                | 64 (21.6%)    | 72 (20.3%) | 0.700        |
| Cyst diameter (≥3 cm)                | 34 (11.5%)    | 37 (10.4%) | 0.706        |
| Transferred embryo stage             |               |           |               |
| Cleavage stage                       | 22 (7.2%)     | 20 (6.5%)  | 0.425        |
| Blastocyte                           | 283 (92.8%)   | 342 (94.5%) |             |
| No. of transferred embryos           | 1.29 ± 0.56   | 1.33 ± 0.51 | 0.965        |
| Estrogen                             | 262.91 ± 294.51 | 293.39 ± 342.17 | 0.331 |
| LH                                   | 18.42 ± 11.66 | 15.19 ± 13.66 | 0.296        |
| Pregnancy rate                       | 49.0%         | 57.7%     | 0.027*       |
| Live birth rate                      | 38.5%         | 45.6%     | 0.080        |
| Preterm birth rate                   | 4.4%          | 11.7%     | 0.040*       |
| Early abortion rate                  | 8.8%          | 11.0%     | 0.362        |
| Late abortion rate                   | 0%            | 0.8%      | 0.255        |
| Ectopic pregnancy rate               | 1.4%          | 0.3%      | 0.183        |

*\( p < 0.05 \), **\( p < 0.01 \).

**TABLE 3 | Multivariable logistic regression analysis.**

| Variables in the equation | \( p \)-value | OR  | 95.0% CI  |
|---------------------------|---------------|-----|-----------|
| Step 1a Group             | 0.023*       | 0.444 | 0.221 | 0.894 |
| Age                       | 0.030*       | 0.900 | 0.818 | 0.990 |
| AMH                       | 0.486        | 1.027 | 0.952 | 1.109 |
| Cyst < 3 cm               | 0.241        | 0.594 | 0.248 | 1.419 |
| Cyst ≥ 3 cm               | 0.015*       | 3.878 | 1.306 | 11.510 |
Moreover, hCG was also reported to regulate progesterone expression via the ERK1/2 pathway (25) and promote human endometrial stromal cell decidualization (13).

Furthermore, an aberrant subset of uterine Natural Killer (uNK) cells was found in the eutopic endometrium of women with EM-associated infertility (26). Immature uNK cell populations exist in infertile women with EM (27), and hCG has been reported as a regulator of uNK cell proliferation, mediated via the mannose receptor (CD206) (28). These findings likely suggest that hCG could improve endometrial receptivity via regulating immune cells in the eutopic endometrium of women with EM-associated infertility.

The main limitation of our study is that only patients with appropriate endometrial thickness and good quality embryos were included. Furthermore, owing to the retrospective design of our study, the stage of EM could not be provided based on the collected data. Further evidence is needed to validate and determine an optimum protocol with maximum beneficial outcomes.

In our research, the pregnancy rate significantly increased after hCG injection in women with EM; however, the difference in live birth rate was not statistically significant with respect to that of controls. This may be the result of insufficient time or dose of hCG that may be improved by replacing single hCG treatments with a repetitive administration scheme (29).

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by research ethics committee of Reproductive Hospital affiliate d to Shandong University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RT designed the study. YD interpreted the data and drafted the article. LY revised the manuscript critically and accounted for all aspects of the work. MS and YS collected all the data. XL and ZF analyzed the data. All the authors contributed equally to this manuscript.

FUNDING

This study was funded by a grant from the National Nature Science Foundation of China (81571414).

ACKNOWLEDGMENTS

We wish to thank the colleagues in our hospital—Qin Gao, Zengxiang Ma, Jingjing Jiang, Hong Liu, Shanshan Gao, Na Yu, and Qiaona Yuan—who offered assistance in this study. This manuscript has been released as a pre-print at Research Square (30).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.592921/full#supplementary-material

REFERENCES

1. Senapati S, Sammel MD, Morse C, Barnhart KT. Impact of endometriosis on in vitro fertilization outcomes: an evaluation of the Society for Assisted Reproductive Technologies Database. Fertil Steril. (2016) 106:164–71 e1. doi: 10.1016/j.fertnstert.2016.03.037

2. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. (2013) 28:1552–68. doi: 10.1093/humrep/deu050

3. Meuleman C, Vandebroek B, Fieuws S, Spieksma C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. (2009) 92:68–74. doi: 10.1016/j.fertnstert.2008.04.036

4. Du YB, Gao MZ, Shi Y, Sun ZG, Wang J. Endocrine and inflammatory factors and endometriosis-associated infertility in assisted reproduction techniques. Arch Gynecol Obstet. (2013) 287:123–30. doi: 10.1007/s00404-012-2567-0

5. Müller JE, Ahn SH, Monsanto SP, Khalaj K, Koti M, Tayade C. Implications of immune dysfunction on endometriosis associated infertility. Oncotarget. (2017) 8:7138–47. doi: 10.18632/oncotarget.12577

6. Lesseby BA, Kim JJ. Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why. Fertil Steril. (2017) 108:19–27. doi: 10.1016/j.fertnstert.2017.05.031

7. May KE, Villar J, Kirtley S, Kennedy SH, Becker CM. Endometrial alterations in endometriosis: a systematic review of putative biomarkers. Hum Reprod Update. (2011) 17:637–53. doi: 10.1093/humupd/dmt013

8. Agbajano 8, Velarde MC, Giudice LC. Altered gene expression profiling in endometrium: evidence for progesterone resistance. Semin Reprod Med. (2010) 28:51–8. doi: 10.1055/s-0029-1242994

9. Mohamed AM, Chouliaaras S, Jones CJ, Nardo LG. Live birth rate in fresh and frozen embryo transfer cycles in women with endometriosis. Eur J Obstet Gynecol Reprod Biol. (2011) 156:177–80. doi: 10.1016/j.ejogrb.2011.01.020

10. Xu Z, Chen W, Chen C, Xiao Y, Chen X. Effect of intrauterine injection of human chorionic gonadotropin before frozen-thawed embryo transfer on pregnancy outcomes in women with endometriosis. J Int Med Res. (2019) 47:2873–80. doi: 10.1177/0300060519848928

11. Puisant E, Van RysSELBERGE M, Barlow P, Deweze J, Leroy F. Embryo scoring as a prognostic tool in IVF treatment. Hum Reprod. (1987) 2:705–8. doi: 10.1093/oxfordjournals.humrep.a136618

12. Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab. (1990) 70:421–30. doi: 10.1210/jcem-70-2-421

13. Koch Y, Wimerberger P, Grummer R. Human chorionic gonadotropin induces decidualization of ectopic human endometrium more effectively than forskolin in an in-vivo endometriosis model. Exp Biol Med (Maywood). (2018) 243:953–62. doi: 10.1177/153370218782658

14. Jurisicova A, Antenos M, Kapasi K, Meriano J, Casper RF. Variability in the expression of trophodermal markers beta-human chorionic gonadotropin, human leukocyte antigen-G and pregnancy specific beta-1 glycoprotein by the human blastocyst. Hum Reprod. (1999) 14:1852–8. doi: 10.1093/humrep/14.7.1852
15. Perrier d’Hauterive S, Berndt S, Tsampalas M, Charlet-Renard C, Dubois M, Bourgain C, et al. Dialogue between blastocyst hCG and endometrial LH/hCG receptor: which role in implantation? *Gynecol Obstet Invest*. (2007) 64:156–60. doi: 10.1159/000101740

16. Braundmeier A, Jackson K, Hastings J, Kochler J, Nowak R, Fazleabas A. Induction of endometriosis alters the peripheral and endometrial regulatory T cell population in the non-human primate. *Hum Reprod*. (2012) 27:1712–22. doi: 10.1093/humrep/des083

17. Berbic M, Hey-Cunningham AJ, Ng C, Tokushige N, Ganewatta S, Markham R, et al. The role of Foxp3+ regulatory T-cells in endometriosis: a potential controlling mechanism for a complex, chronic immunological condition. *Hum Reprod*. (2010) 25:900–7. doi: 10.1093/humrep/der020

18. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. *Mol Cell Endocrinol.* (2006) 248:94–103. doi: 10.1016/j.mce.2005.11.041

19. Wolffer MM, Kuppers M, Rath W, Buck VU, Meinhold-Heerlein I, Claessen-Linke I. Altered expression of progesterone receptor isoforms A and B in human eutopic endometrium in endometriosis patients. *Ann Anat.* (2016) 206:1–6. doi: 10.1016/j.aanat.2016.03.004

20. Lessey BA, Castelbaum AJ, Sawin SW, Buck CA, Schinnar R, Bilker W, et al. Aberrant integrin expression in the endometrium of women with endometriosis. *J Clin Endocrinol Metab.* (1994) 79:643–9. doi: 10.1210/jcem.79.2.7519194

21. Miller PB, Parnell BA, Bushnell G, Tallman N, Forstein DA, Higdon HL, III, et al. Endometrial receptivity defects during IVF cycles with and without letrozole. *Hum Reprod*. (2012) 27:881–8. doi: 10.1093/humrep/der452

22. Huber A, Huddelst G, Knoller M, Saleh L, Huber JC, Singer CF. Effect of highly purified human chorionic gonadotropin preparations on the gene expression signature of stromal cells derived from endometriotic lesions: potential mechanisms for the therapeutic effect of human chorionic gonadotropin in vivo. *Fertil Steril.* (2007) 88:1232–9. doi: 10.1016/j.fertnstert.2007.02.006

23. Du Y, Taylor HS. The role of hox genes in female reproductive tract development, adult function, and fertility. *Cold Spring Harb Perspect Med*. (2015) 6:a023002. doi: 10.1101/cshperspect.a023002

24. Fogle RH, Li A, Paulson Rl. Modulation of HOXA10 and other markers of endometrial receptivity by age and human chorionic gonadotropin in an endometrial explant model. *Fertil Steril.* (2010) 93:1255–9. doi: 10.1016/j.fertnstert.2008.11.002

25. Tapia-Pizarro A, Archiles S, Argaranda F, Valencia C, Zavaleta K, Cecilia Johnson M, et al. hCG activates Epac-Erk1/2 signaling regulating Progesterone Receptor expression and function in human endometrial stromal cells. *Mol Hum Reprod*. (2017) 23:393–405. doi: 10.1093/molehr/gax015

26. Giuliani E, Parkin KL, Lessey BA, Young SL, Fazleabas AT. Characterization of uterine NK cells in women with infertility or recurrent pregnancy loss and associated endometriosis. *Am J Reprod Immunol*. (2014) 72:262–9. doi: 10.1111/aji.12259

27. Thiruchelvam U, Wingfield M, O’Farrelly C. Increased uNK progenitor cells in women with endometriosis and infertility are associated with low levels of endometrial stem cell factor. *Am J Reprod Immunol*. (2016) 75:493–502. doi: 10.1111/aji.12486

28. Kane N, Kelly R, Saunders PT, Critchley HO. Proliferation of uterine natural killer cells is induced by human chorionic gonadotropin and mediated via the mannose receptor. *Endocrinology*. (2009) 150:2882–8. doi: 10.1210/en.2008-1309

29. Makrigiannakis A, Vrekoussis T, Zoumakis E, Kalantaridou SN, Jeschke U. The role of HCG in implantation: a mini-review of molecular and clinical evidence. *Int J Mol Sci.* (2017) 18:1305. doi: 10.3390/ijms18061305

30. Du Y, Yan L, Sun M, Sheng Y, Li X, Feng Z, et al. Effect of human chorionic gonadotropin injection before frozen embryo transfer on pregnancy outcomes in endometriosis infertility. *Research Square [preprint]*. (2020). doi: 10.21203/rs.3.rs-15724/v1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Du, Yan, Sun, Sheng, Li, Feng and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.